Kim Lauper
About
Kim Lauper is a scholar working on Rheumatology, Immunology and Infectious Diseases.
According to data from OpenAlex, Kim Lauper has authored 41 papers receiving a total of 947 indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Rheumatology, 12 papers in Immunology and 8 papers in Infectious Diseases. Recurrent topics in Kim Lauper's work include Rheumatoid Arthritis Research and Therapies (24 papers), Biosimilars and Bioanalytical Methods (7 papers) and Autoimmune and Inflammatory Disorders Research (6 papers). Kim Lauper is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (24 papers), Biosimilars and Bioanalytical Methods (7 papers) and Autoimmune and Inflammatory Disorders Research (6 papers). Kim Lauper collaborates with scholars based in Switzerland, United States and United Kingdom. Kim Lauper's co-authors include Axel Finckh, Benoît Gilbert, D. Alpizar-Rodriguez, Sang‐Cheol Bae, Bridget Hodkinson, Kevin D. Deane, Ranjeny Thomas, Cem Gabay, Delphine S. Courvoisier and Denis Mongin and has published in prestigious journals such as Clinical Infectious Diseases, Frontiers in Immunology and Annals of the Rheumatic Diseases.
In The Last Decade
Kim Lauper
37 papers receiving 931 citations
Hit Papers
Peers
Kim Lauper
Vir Singh Negi India
Katie Bechman United Kingdom
Elena Massarotti United States
David Liew Australia
Bridget Hodkinson South Africa
Orazio De Lucia Italy
Sergey Moiseev Russia
Martina Biggioggero Italy
Sung‐Hoon Park South Korea
Sebastian E. Sattui United States
Citations per year, relative to Kim Lauper Kim Lauper (= 1×)
peers
Vir Singh Negi
Countries citing papers authored by Kim Lauper
Since
Specialization
Citations
This map shows the geographic impact of Kim Lauper's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kim Lauper with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kim Lauper more than expected).
Fields of papers citing papers by Kim Lauper
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Kim Lauper. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kim Lauper. The network helps show where Kim Lauper may publish in the future.
Co-authorship network of co-authors of Kim Lauper
This figure shows the co-authorship network connecting the top 25 collaborators of Kim Lauper. A scholar is included among the top collaborators of Kim Lauper based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kim Lauper. Kim Lauper is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Lauper, Kim, Diana Buitrago‐García, Delphine S. Courvoisier, Michele Iudici, & Denis Mongin. (2025). Trends and influences in women authorship in randomised controlled trials in rheumatology: a comprehensive analysis of all published RCTs from 2009 to 2023. RMD Open. 11(1). e005341–e005341.
2.
Sepriano, Alexandre, Elena Nikiphorou, René Østgård, et al.. (2024). A Systematic Overview of Contraindications and Special Warnings for Biologic and Targeted Synthetic Disease Modifying Antirheumatic Drugs: Establishing a Framework to Create a “Safety Checklist”. Drug Safety. 47(11). 1075–1093.
3.
Juge, Pierre‐Antoine, Tue Wenzel Kragstrup, Luis Fernando Pérez-García, et al.. (2024). Evaluating the participation of junior members and patient and healthcare professionals representatives in EULAR task forces: results from an international survey. RMD Open. 10(2). e004177–e004177.
4.
Gilbert, Benoît, Denis Mongin, Kim Lauper, et al.. (2024). Comparative effectiveness of baricitinib and alternative biological DMARDs in a Swiss cohort study of patients with RA. BMJ Open. 14(3). e072300–e072300.
5.
Lamacchia, Céline, Sébastien Aeby, Carole Kebbi‐Beghdadi, et al.. (2023). A potential role for chlamydial infection in rheumatoid arthritis development. Lara D. Veeken. 64(1). 252–260.
6.
Lauper, Kim, Lianne Kearsley‐Fleet, James Galloway, et al.. (2023). Evaluation of serious infections, including Mycobacterium tuberculosis, during treatment with biologic disease-modifying anti-rheumatic drugs: does line of therapy matter?. Lara D. Veeken. 63(7). 1957–1964.
7.
Lamacchia, Céline, et al.. (2023). Brief report: can COVID-19 infection trigger rheumatoid arthritis-associated autoimmunity in individuals at risk for the disease? A nested cohort study. Frontiers in Medicine. 10. 1201425–1201425.
8.
Gilbert, Benoît, et al.. (2023). POS0531 EVALUATION OF THE KNOWLEDGE OF INTERNAL MEDICINE PHYSICIANS, FINAL-YEAR MEDICAL STUDENTS AND RHEUMATOLOGISTS REGARDING THE DIAGNOSIS AND MANAGEMENT OF GOUT IN SWITZERLAND. Annals of the Rheumatic Diseases. 82. 529–529.
9.
Courvoisier, Delphine S., Kim Lauper, Joanna Kedra, et al.. (2022). EULAR points to consider when analysing and reporting comparative effectiveness research using observational data in rheumatology. Annals of the Rheumatic Diseases. 81(6). 780–785.
10.
Finckh, Axel, Benoît Gilbert, Bridget Hodkinson, et al.. (2022). Global epidemiology of rheumatoid arthritis. Nature Reviews Rheumatology. 18(10). 591–602.
11.
Lauper, Kim, Gautier Bréville, Rachel Goldstein, et al.. (2021). Robust T-Cell Responses in Anti-CD20-Treated Patients Following COVID-19 Vaccination: A Prospective Cohort Study. Clinical Infectious Diseases. 75(1). e1037–e1045.
12.
Lauper, Kim, Joanna Kedra, Maarten de Wit, et al.. (2021). Analysing and reporting of observational data: a systematic review informing the EULAR points to consider when analysing and reporting comparative effectiveness research with observational data in rheumatology. RMD Open. 7(3). e001818–e001818.
13.
Gilbert, Benoît, Céline Lamacchia, Denis Mongin, et al.. (2021). Cohort profile: SCREEN-RA: design, methods and perspectives of a Swiss cohort study of first-degree relatives of patients with rheumatoid arthritis. BMJ Open. 11(7). e048409–e048409.
14.
Lauper, Kim, J. W. J. Bijlsma, & Gerd R Burmester. (2020). Trajectories of COVID-19 information in the Annals of the Rheumatic Diseases: the first months of the pandemic. Annals of the Rheumatic Diseases. 80(1). 26–30.
15.
Lauper, Kim, et al.. (2019). SAT0588 COMPARATIVE EFFECTIVENESS RESEARCH IN OBSERVATIONAL SETTINGS: EVALUATING TWO NEW METHODS TO ANALYSE RESPONSE RATES. Annals of the Rheumatic Diseases. 78. 1386–1388.
16.
Mongin, Denis, Kim Lauper, Carl Turesson, et al.. (2019). Imputing missing data of function and disease activity in rheumatoid arthritis registers: what is the best technique?. RMD Open. 5(2). e000994–e000994.
17.
Cheval, Boris, Stéphane Cullati, Denis Mongin, et al.. (2019). Associations of regrets and coping strategies with job satisfaction and turnover intention: international prospective cohort study of novice healthcare professionals. Swiss Medical Weekly. 149(1718). w20074–w20074.
18.
Lauper, Kim, Denis Mongin, Florenzo Iannone, et al.. (2019). Comparative effectiveness of TNF inhibitors and tocilizumab with and without conventional synthetic disease-modifying antirheumatic drugs in a pan-European observational cohort of bio-naïve patients with rheumatoid arthritis. Seminars in Arthritis and Rheumatism. 50(1). 17–24.
19.
Lauper, Kim, Dan Nordström, Karel Pavelká, et al.. (2018). Comparative effectiveness of tocilizumab versus TNF inhibitors as monotherapy or in combination with conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis after the use of at least one biologic disease-modifying antirheumatic drug: analyses from the pan-European TOCERRA register collaboration. Annals of the Rheumatic Diseases. 77(9). 1276–1282.
20.
Alpizar-Rodriguez, D., Laure Brulhart, Ruediger B. Müeller, et al.. (2017). The prevalence of anticitrullinated protein antibodies increases with age in healthy individuals at risk for rheumatoid arthritis. Clinical Rheumatology. 36(3). 677–682.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Vir Singh Negi Breakdown of academic impact, for papers by Katie Bechman Breakdown of academic impact, for papers by Elena Massarotti Breakdown of academic impact, for papers by David Liew Breakdown of academic impact, for papers by Bridget Hodkinson Breakdown of academic impact, for papers by Orazio De Lucia Breakdown of academic impact, for papers by Sergey Moiseev Breakdown of academic impact, for papers by Martina Biggioggero Breakdown of academic impact, for papers by Sung‐Hoon Park Breakdown of academic impact, for papers by Sebastian E. Sattui